Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07179380 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A Phase 3 study of Pulmonary Hypertension and Interstitial Lung Disease, sponsored by Insmed Incorporated.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 344
- Enrollment target
- 20
- Study locations
NCT07179380: Recruiting Phase 3 study of Pulmonary Hypertension and Interstitial Lung Disease, sponsored by Insmed Incorporated.
NCT07179380 is a Phase 3 study of Pulmonary Hypertension and Interstitial Lung Disease that is actively recruiting participants, run by Insmed Incorporated. The registered enrollment target is 344 participants, below the 609-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07179380, a Phase 3 study of Pulmonary Hypertension and Interstitial Lung Disease, is actively recruiting participants, sponsored by Insmed Incorporated.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 344 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Treprostinil Palmitil Inhalation Powder
Study Locations (20)
Other
- GEO002 - Tbilisi
- GEO004 - Tbilisi
- GEO003 - Tbilisi
- GEO001 - Tbilisi
- DEU010 - Gauting
- ISR001 - Haifa
- ISR002 - Jerusalem
- ISR004 - Tel Aviv
Chiba
- JPN002 - Narashino-shi
- JPN004 - Narita
California
- USA001 - Santa Barbara
Florida
- USA006 - Naples
Oregon
- USA003 - Bend
Virginia
- USA008 - Richmond
Bavaria
- DEU003 - München
Hesse
- DEU005 - Immenhausen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2026-01-07 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 3 |
What NCT07179380 shows while recruiting
NCT07179380 is an interventional study that assigns participants to a tested intervention. The registered 344 participants enrollment target is mid-sized for trials with a published cap, below the 609-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (44% lower).
The record links to 2 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07179380 names 20 study sites across 12 states, led by Other, Chiba, California.
Frequently Asked Questions
What is clinical trial NCT07179380 about?
NCT07179380 is a clinical study titled "Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)". The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
What is the current status of trial NCT07179380?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 344 participants. The study started on 2026-01-07. Estimated completion is 2028-12-30.
What conditions does trial NCT07179380 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Interstitial Lung Disease.
What interventions are being tested in trial NCT07179380?
The interventions under investigation include: Placebo (DRUG), Treprostinil Palmitil Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT07179380?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07179380 being conducted?
This trial has 20 study locations across California, Florida, Oregon, Virginia, Bavaria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07179380's enrollment target sits among peer trials
344 13th of 72 higher than 60 of 72 other Pulmonary Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
RECRUITING · Phase 3
-
Safety and Efficacy of FETO in CDH Phase III
RECRUITING · Phase 3
-
Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)
COMPLETED · Phase 3
-
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
COMPLETED · Phase 3
-
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
COMPLETED · Phase 3
-
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06733363 · 344 participants · Phase 2
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
- NCT07304024 · 344 participants · Phase 1
A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
- NCT03972657 · 345 participants · Phase 1
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- NCT05107674 · 345 participants · Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI